ArticleWorld journal of gastroenterology2014
Experimental models of non-alcoholic fatty liver disease in rats.
Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed.
- Danshao Shugan Granule therapy for non-alcoholic fatty liver disease.Lipids in health and disease · 2022Trial
- Low-Dose, Long-TermInternational journal of molecular sciences · 2026Article
- Paradoxical oncogenic effects of hepatic Brca1 through modulating Bhmt.Scientific reports · 2026Article
- Metformin mitigates metabolic dysfunction-associated steatohepatitis in rats by altering steatosis-related micro-RNAs and Aquaporin-9.Journal of molecular histology · 2026Article
- Repeatability and Variability of a High-Fat High-Fructose Diet-Induced Metabolic Syndrome Model in Young Adult Male Wistar Rats.Methods and protocols · 2026Article
- A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics.Frontiers in toxicology · 2026Article
- Article
- 3D multiparametric ultrasound imaging of steatotic liver disease in a study with male rats.Nature communications · 2025Article
- Luteolin Relieves Metabolic Dysfunction-Associated Fatty Liver Disease Caused by a High-Fat Diet in Rats Through Modulating the AdipoR1/AMPK/PPARγ Signaling Pathway.International journal of molecular sciences · 2025Article
- Association between TyG-related parameters and NAFLD risk in Japanese non-obese population.Scientific reports · 2025Article
- Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model.Scientific reports · 2025Article
- Pathophysiological Role of Neutrophil Extracellular Traps in Diet-Induced Obesity and Metabolic Syndrome in Animal Models.Nutrients · 2025Review
- The possible protective effect of luteolin on cardiovascular and hepatic changes in metabolic syndrome rat model.Cell and tissue research · 2025Article
- An integrative pharmacology-based study on the pharmacological activity and mechanism of xiaoji-chenpi formula (XCF) against MAFLD.Frontiers in pharmacology · 2025Article
- Hepatic stereological analysis in obese Zucker rats (Leprfa) with dyslipidemia.Acta cirurgica brasileira · 2025Article
- Liver Histomorphological Changes in First- and Second-Generation Rat Offspring Associated With Maternal Undernutrition.Canadian journal of gastroenterology & hepatology · 2025Article
- TAT as a new marker and its use for noninvasive chemical biopsy in NASH diagnosis.Molecular medicine (Cambridge, Mass.) · 2024Article
- Non-Targeted Metabolomics Reveal Apomorphine's Therapeutic Effects and Lysophospholipid Alterations in Steatohepatitis.Antioxidants (Basel, Switzerland) · 2024Article
- Assessment of melatonin's therapeutic effectiveness against hepatic steatosis induced by a high-carbohydrate high-fat diet in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Effects of different maternal diets on adipose tissue inflammation and liver tissue oxidative stress in dams and their female offspring.Molecular and cellular biochemistry · 2024Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world, and it persists at a high prevalence. NAFLD is characterised by the accumulation of triglycerides in the liver and includes a spectrum of histopathological findings, ranging from simple fatty liver through non-alcoholic steatohepatitis (NASH) to fibrosis and ultimately cirrhosis, which may progress to hepatocellular carcinoma. The pathogenesis of NAFLD is closely related to the metabolic syndrome and insulin resistance. Understanding the pathophysiology and treatment of NAFLD in humans has currently been limited by the lack of satisfactory animal models. The ideal animal model for NAFLD should reflect all aspects of the intricate etiopathogenesis of human NAFLD and the typical histological findings of its different stages. Within the past several years, great emphasis has been placed on the development of an appropriate model for human NASH. This paper reviews the widely used experimental models of NAFLD in rats. We discuss nutritional, genetic and combined models of NAFLD and their pros and cons. The choice of a suitable animal model for this disease while respecting its limitations may help to improve the understanding of its complex pathogenesis and to discover appropriate therapeutic strategies. Considering the legislative, ethical, economical and health factors of NAFLD, animal models are essential tools for the research of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.